Nasdaq

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...
Nasdaq

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Nature

Precise disease heterogeneity and progression quantification in MSA and Parkinson’s disease using machine learning

Disease progression in multiple system atrophy (MSA) and Parkinson’s disease (PD) shows marked patient-to-patient heterogeneity. We hypothesize that machine learning methods applied to multimodal MRI ...